ATHE - Alterity begins phase 2 trial for multiple system atrophy treatment in Italy

• Alterity Therapeutics ( NASDAQ: ATHE ) is trading 3% higher premarket after it said it begun enrollment in Italy for its Phase 2 trial of ATH434 to treat Multiple System Atrophy ( MSA ).
• The study will test ATH434 treatment on neuroimaging and protein biomarkers to demonstrate target engagement and clinical endpoints to demonstrate efficacy, in addition to assessments of safety and pharmacokinetics.
• The study is expected to enroll about 60 patients to receive one of two dose levels of ATH434 or placebo.
• "Our trial sites in Europe, Asia-Pacific, and the U.S. are now actively recruiting participants with early-stage MSA as we continue our commitment to bring a much-needed treatment to individuals living with this devastating condition," the company said.

For further details see: